Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000947871-26-000193·ORBIMED ADVISORS LLC
Schedule 13G ownership disclosure
Vistagen Therapeutics Inc
Common Stock, par value $0.001 per share · CUSIP: 92840H400
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ORBIMED ADVISORS LLC
Shares: 1,420,300.00 · Class: 3.6%
- ORBIMED CAPITAL LLC
Shares: 1,639,700.00 · Class: 4.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-26-000193
- Form type
- SCHEDULE 13G/A
- Filer
- ORBIMED ADVISORS LLC
- CIK
- CIK 1055951
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership